Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M
Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, University of Tokushima, Japan.
Cancer. 1993 Aug 15;72(4):1386-93. doi: 10.1002/1097-0142(19930815)72:4<1386::aid-cncr2820720439>3.0.co;2-j.
The Gs alpha (Gs alpha) gene can be activated to the putative oncogene gsp by specific point mutations at codons 201 or 227. Such mutations have been reported in growth hormone (GH)-secreting pituitary adenomas and thyroid tumors. To clarify the role of Gs alpha gene in human endocrine tumors, 197 tumors were screened for point mutations at codons 201 or 227 of the Gs alpha gene.
Mutations were detected by primer-introduced restriction analysis (PIRA) of the polymerase chain reaction (PCR) product of genomic DNA.
These Gs alpha mutations were present in 4 of 53 pituitary adenomas (4 of 43 GH-secreting adenomas; 1 of these 4 was a GH- and prolactin-secreting adenoma from a patient with familial multiple endocrine neoplasia Type 1), 4 of 66 thyroid tumors (4 of 30 papillary carcinomas), and 1 of 19 adrenocortical adenomas (1 of 6 aldosterone-secreting adenomas). In contrast, none of these Gs alpha mutations were detected in parathyroid tumors, endocrine pancreatic tumors, or pheochromocytomas.
Gs alpha mutations at these two loci may play a role in the pathogenesis of a small population of GH-secreting pituitary adenomas, papillary thyroid carcinomas, and adrenocortical adenomas, but that they are not involved in the pathogenesis of other types of endocrine tumors.
Gsα基因可通过第201或227密码子的特定点突变激活为假定的癌基因gsp。此类突变已在分泌生长激素(GH)的垂体腺瘤和甲状腺肿瘤中报道。为阐明Gsα基因在人类内分泌肿瘤中的作用,对197个肿瘤进行了Gsα基因第201或227密码子点突变的筛查。
通过对基因组DNA聚合酶链反应(PCR)产物进行引物引入限制性分析(PIRA)检测突变。
这些Gsα突变存在于53个垂体腺瘤中的4个(43个分泌GH的腺瘤中的4个;这4个中有1个是来自1型家族性多发性内分泌腺瘤患者的分泌GH和催乳素的腺瘤)、66个甲状腺肿瘤中的4个(30个乳头状癌中的4个)以及19个肾上腺皮质腺瘤中的1个(6个分泌醛固酮的腺瘤中的1个)。相比之下,在甲状旁腺肿瘤、内分泌胰腺肿瘤或嗜铬细胞瘤中未检测到这些Gsα突变。
这两个位点的Gsα突变可能在一小部分分泌GH的垂体腺瘤、乳头状甲状腺癌和肾上腺皮质腺瘤的发病机制中起作用,但它们不参与其他类型内分泌肿瘤的发病机制。